Choosing the Right P-Value for Clinical Drug Trials
This paper examines the question of what constitutes an appropriate p-value for clinical drug trials. It begins by explaining what the p-value represents and how it is used to accept or reject a null hypothesis. The paper then argues that while a significance threshold of .05 may be acceptable in business or marketing research, the potential human costs associated with drug trials warrant a stricter standard, such as .01. Drawing on the Vioxx case as a cautionary example, the paper weighs the trade-offs between reducing harm from dangerous side effects and ensuring that beneficial treatments reach patients who need them. It concludes that p-value selection must account for multiple contextual factors, including sample representativeness and the nature of the hypothesis being tested.
- Introduction to P-Values and Statistical Significance: Defines p-value and null hypothesis testing
- Why Drug Trials Demand a Stricter Standard: Human costs justify lower p-value thresholds
- Balancing Human Cost and Treatment Benefit: Trade-offs between harm reduction and access
- Contextual Factors in Choosing a P-Value: Sample bias and concurrent hypotheses complicate decisions
- Conclusion: Context-sensitive p-value selection is essential
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- Uses a concrete, accessible example (counting M&M's) to explain the abstract concept of a p-value before applying it to the high-stakes context of drug trials.
- Grounds the argument in a real-world case — the Vioxx scandal — to illustrate the human consequences of inadequate statistical thresholds.
- Maintains intellectual balance by acknowledging that a stricter p-value is not always preferable, particularly when a treatment may benefit a large number of patients with no alternatives.
Key academic technique demonstrated
The paper demonstrates applied quantitative reasoning by translating abstract probability thresholds into concrete human-impact estimates (e.g., 50,000 harmed at .05 versus 10,000 at .01 in a population of one million). This technique of operationalizing statistical concepts into real-world numbers strengthens the argument without requiring additional data sources.
Structure breakdown
The paper opens by defining the p-value and its role in hypothesis testing, then moves to the specific demands of clinical research, using Vioxx as a pivotal example. It proceeds to weigh the costs and benefits of stricter thresholds, introduces complicating factors such as sample representativeness, and closes with a call for context-sensitive decision-making. The argument builds logically from definition to application to nuanced judgment.
Introduction to P-Values and Statistical Significance
Statistical testing to determine whether results are significant is extremely useful in all types of research. In most cases, when a significance level — or p-value — is being chosen, a value of .05 is deemed to be sufficiently accurate. However, while this may be suitable for many types of research, it can be argued that in clinical trials for drugs, a lower p-value may be more appropriate, given the nature of the research. To understand this, it is necessary to first understand what the p-value is and what it signifies.
The p-value gives a probability, but it is easy to misunderstand, as it indicates the level of support for the null hypothesis — that is, the probability level used to determine whether to accept or reject the null hypothesis. The p-value provides the probability of obtaining an effect at the same level if the null hypothesis were true (Cowen, 1997). For example, if testing a basic hypothesis that there are at least twenty sweets in a packet of M&Ms, with a null hypothesis that there are not twenty sweets in the packet, and the p-value is 0.04, this would mean there is only a 4% chance of the null hypothesis being true in that sample. Since the cut-off was .05, the null hypothesis could be rejected and the original hypothesis accepted (Cowen, 1997).
References
Berenson, A. (2006, May 31). Merck admits a data error on Vioxx. The New York Times. Retrieved November 13, 2015, from http://www.nytimes.com/2006/05/31/business/31drug.html?_r=0
Cowen, G. (1997). Statistical data analysis. Oxford: Oxford University Press.
Create your account
Always verify citation format against your institution’s current style guide requirements.